Abstract
Thirty-seven liver-grafted patients with steroid-resistant acute or chronic graft rejection or with cyclosporin-related complications were converted from CyA to FK 506. The clinical outcome of the patients primarily depended on the degree of liver dysfunction present at initiation of FK 506 treatment. In patients switched to FK 506 for treatment of acute or early chronic graft rejection, CyA nephrotoxicity, or CyA malabsorption, the FK 506 therapy was associated with a clear improvement in the clinical course. In contrast, in patients with advanced chronic graft rejection, a lower response rate to the conversion in immunosuppression was observed. The lower response rate was associated with a higher patient mortality. These studies demonstrate that FK 506 represents a valuable alternative immunosuppressant for liver-grafted patients. The conversion from CyA to FK 506 should take place before serious — and potentially irreversible — disturbances in liver function are observed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abu-Elmagd K, Fung JJ, Alessiani M, Jain A, Venkataramanan R, Warty VS, Takaya S, Todo S, Shannon WD, Starzl TE (1991) The effect of graft function on FK 506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation 52: 71
Brinkmann C, Jost U, Winkler M, Ringe B, Pichlmayr R (1992) Cyclosporin-Nebenwirkungen im Langzeitverlauf nach Leber-transplantation. Z Tx Med 3 [Suppl 1]: 12
Christians U, Braun F, Kosian N, Schmidt M, Schübel H, Ernst L, Kruse C, Winkler M, Holze I, Linck A, Sewing KF (1991) High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile and urine of liver grafted patients. Transplant Proc 23: 2741
Christians U, Braun F, Schmidt M, Kosian N, Schübel H, Ernst L, Winkler M, Kruse C, Linck A, Sewing K-F (1992) Specific and sensitive measurement of FK 506 and its metabolites in blood and urine of liver grafted patients. Clin Chem 38: 2025
Cillo U, Alessiani M, Fung J, Todo S, Tzakis A, Starzl TE (1993) Major adverse effects of FK 506 used as an immunosuppressive agent after liver transplantation. Transplant Proc 25: 628–634
Fung JJ, Todo S, Tzakis A, Demetris AJ, Jain A, Abu-Elmagd K, Alessiani M, Starzl TE (1991) Conversion of liver allograft recipients from cyclosporine to FK 506 based immunosuppression: benefits and pitfalls. Transplant Proc 23: 14
Jain AB, Venkataramanan R, Cadoff E, Fung JJ, Todo S, Krajack A, Starzl TE (1990) Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc 22: 57
Jusko WJ, Ambrosio RD (1991) Monitoring FK 506 concentrations in plasma and whole blood. Transplant Proc 23: 2732
Kobayashi M, Tamura K, Katayama N, Nakamura K, Nagase K, Hane K, Tutumi T, Niwa M, Tanaka H, Iwasaki K, Kohsaka M (1991) FK 506 assay past and present-characteristics of FK 506 ELISA. Transplant Proc 23: 2725
Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE (1991) New onset diabetes in FK 506 vs cyclosporine treated kidney transplant recipients. Transplant Proc 23: 3169
Schlitt HJ, Ringe B, Wittekind C, Nashan B, Wonigeit K, Pichlmayr R (1990) Die klinische Bedeutung der Transplantatbiopsie für die Behandlung lebertransplantierter Patienten. Z Tx Med 1: 17
Shapiro R, Fung JJ, Jain AB, Parks P, Todo S, Starzl TE (1990) The side effects of FK 506 in humans. Transplant Proc 22: 35
Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramanan R, Jain A (1989) FK 506 for human liver, kidney and pancreas transplantation. Lancet II: 1000
Tamura K, Kobayashi M, Hashimoto K, Nakamura K (1987) A highly sensitive method to assay FK-506 levels in plasma. Transplant Proc 19: 23
Todo S, Fung JJ, Starzl TE, Tzakis A, Demetris AJ, Kormos R, Jain A, Alessiani M, Takaya S, Shapiro R (1990) Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg 212: 295
Winkler M, Lost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R (1991) Association of high FK 506 plasma levels with nephrotoxicity in liver grafted patients. Transplant Proc 23: 3153
Author information
Authors and Affiliations
About this article
Cite this article
Winkler, M., Ringe, B., Jost, U. et al. Conversion from cyclosporin to FK 506 after liver transplantation. Transplant Int 6, 319–324 (1993). https://doi.org/10.1007/BF00335968
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00335968